11-dehydro-TXB2

11-dehydro-txb2 is a lipid of Fatty Acyls (FA) class. 11-dehydro-txb2 is associated with abnormalities such as endothelial dysfunction, Risk factor, cardiovascular, Acute coronary syndrome, thrombocytosis and Chronic ischemic heart disease NOS. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and Lipid Peroxidation. The associated genes with 11-dehydro-TXB2 are PTGS2 gene.

Cross Reference

Introduction

To understand associated biological information of 11-dehydro-TXB2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with 11-dehydro-TXB2?

11-dehydro-TXB2 is suspected in endothelial dysfunction, Risk factor, cardiovascular, Acute coronary syndrome, thrombocytosis, Chronic ischemic heart disease NOS, Diabetes Mellitus and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 11-dehydro-TXB2

MeSH term MeSH ID Detail
Diabetes Mellitus D003920 90 associated lipids
Inflammation D007249 119 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Asthma D001249 52 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Thrombosis D013927 49 associated lipids
Cerebral Hemorrhage D002543 13 associated lipids
Brain Ischemia D002545 89 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Polycythemia Vera D011087 13 associated lipids
Hyperlipidemias D006949 73 associated lipids
Blood Platelet Disorders D001791 12 associated lipids
Albuminuria D000419 18 associated lipids
Renal Artery Obstruction D012078 8 associated lipids
Atrial Fibrillation D001281 16 associated lipids
Atherosclerosis D050197 85 associated lipids
Death, Sudden, Cardiac D016757 12 associated lipids
Hypoalphalipoproteinemias D052456 5 associated lipids
Per page 10 20 | Total 20

PubChem Associated disorders and diseases

What pathways are associated with 11-dehydro-TXB2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with 11-dehydro-TXB2?

There are no associated biomedical information in the current reference collection.

What functions are associated with 11-dehydro-TXB2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with 11-dehydro-TXB2?

There are no associated biomedical information in the current reference collection.

What genes are associated with 11-dehydro-TXB2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with 11-dehydro-TXB2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with 11-dehydro-TXB2

Download all related citations
Per page 10 20 50 100 | Total 289
Authors Title Published Journal PubMed Link
Djurup R et al. Rapid, direct enzyme immunoassay of 11-keto-thromboxane B2 in urine, validated by immunoaffinity/gas chromatography-mass spectrometry. 1993 Clin. Chem. pmid:8252718
Smith SR et al. Chronic thromboxane synthase inhibition with CGS 12970 in human cyclosporine nephrotoxicity. 1993 Transplantation pmid:8279014
van Kooten F et al. Evidence for episodic platelet activation in acute ischemic stroke. 1994 Stroke pmid:8303731
Foegh ML et al. Urinary thromboxane A2 metabolites in patients presenting in the emergency room with acute chest pain. 1994 J. Intern. Med. pmid:8308478
Chiabrando C et al. Urinary excretion and origin of 11-dehydro-2,3-dinor-thromboxane B2 in man. 1993 Prostaglandins pmid:8321910
Takasaki W et al. Superiority of plasma 11-dehydro-TXB2 to TXB2 as an index of in vivo TX formation in rabbits after dosing of CS-518, a TX synthase inhibitor. 1993 Thromb. Res. pmid:8367836
Schiff E et al. Reduction of thromboxane A2 synthesis in pregnancy by polyunsaturated fatty acid supplements. 1993 Am. J. Obstet. Gynecol. pmid:8420313
Van Assche FA et al. Increased thromboxane formation in diabetic pregnancy as a possible contributor to preeclampsia. 1993 Am. J. Obstet. Gynecol. pmid:8420355
Koudstaal PJ et al. Increased thromboxane biosynthesis in patients with acute cerebral ischemia. 1993 Stroke pmid:8421822
Foulon I et al. Increased in vivo production of thromboxane in patients with sickle cell disease is accompanied by an impairment of platelet functions to the thromboxane A2 agonist U46619. 1993 Arterioscler. Thromb. pmid:8443146
Chen HI et al. Effects of exercise training on the biosynthesis of prostacyclin and thromboxane in rats. 1993 Acta Physiol. Scand. pmid:8452036
Ciabattoni G et al. Aspirin, but not heparin, suppresses the transient increase in thromboxane biosynthesis associated with cardiac catheterization or coronary angioplasty. 1993 J. Am. Coll. Cardiol. pmid:8473644
Yasu T et al. Effects of aspirin DL-lysine on thrombin generation in unstable angina pectoris. 1993 Am. J. Cardiol. pmid:8480641
Yamanaka S et al. 11-Dehydro thromboxane B2: a reliable parameter of thromboxane A2 production in dogs. 1993 Prostaglandins pmid:8484010
Stein CM et al. Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. 1996 Arthritis Rheum. pmid:8670323
Laffi G et al. Defective aggregation in cirrhosis is independent of in vivo platelet activation. 1996 J. Hepatol. pmid:8738730
Cuiper LL et al. Systemic and pulmonary hypertension after abrupt cessation of prostacyclin: role of thromboxane A2. 1996 J. Appl. Physiol. pmid:8847301
Schaefer WR et al. Urinary excretion of 2,3-dinor-6-keto-PGF1 alpha and 11-dehydro-TXB2 by the gravid spontaneously hypertensive rat. 1996 Prostaglandins pmid:8875634
Milani M et al. Effects of two different HMG-CoA reductase inhibitors on thromboxane production in type IIA hypercholesterolemia. 1996 Biomed. Pharmacother. pmid:8952866
Reilly M et al. Modulation of oxidant stress in vivo in chronic cigarette smokers. 1996 Circulation pmid:8964113
Bröijersén A et al. No influence of simvastatin treatment on platelet function in vivo in patients with hypercholesterolemia. 1997 Arterioscler. Thromb. Vasc. Biol. pmid:9081681
Oosaki R et al. Urinary leukotriene E4 and 11-dehydrothromboxane B2 in patients with aspirin-sensitive asthma. 1997 Allergy pmid:9188934
Malini PL et al. Thromboxane antagonism and cough induced by angiotensin-converting-enzyme inhibitor. 1997 Lancet pmid:9217714
Rautanen M et al. Experimental fat embolism induces urine 2,3-dinor-6-ketoprostaglandin F1alpha and 11-dehydrothromboxane B2 excretion in pigs. 1997 Crit. Care Med. pmid:9233750
van Kooten F et al. Platelet activation and lipid peroxidation in patients with acute ischemic stroke. 1997 Stroke pmid:9259748
Lahoz C et al. Effects of dietary fat saturation on eicosanoid production, platelet aggregation and blood pressure. 1997 Eur. J. Clin. Invest. pmid:9352251
Farker K et al. Measurements of urinary prostaglandins in young ovulatory women during the menstrual cycle and in postmenopausal women. 1997 Prostaglandins pmid:9373880
Davi G et al. In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia. 1997 Arterioscler. Thromb. Vasc. Biol. pmid:9409316
Davì G et al. Enhanced thromboxane biosynthesis in patients with chronic obstructive pulmonary disease. The Chronic Obstructive Bronchitis and Haemostasis Study Group. 1997 Am. J. Respir. Crit. Care Med. pmid:9412557
Oosaki R et al. Urinary excretion of leukotriene E4 and 11-dehydrothromboxane B2 in patients with spontaneous asthma attacks. 1997 Int. Arch. Allergy Immunol. pmid:9414142
Forastiero R et al. Anti-beta2 glycoprotein I antibodies and platelet activation in patients with antiphospholipid antibodies: association with increased excretion of platelet-derived thromboxane urinary metabolites. 1998 Thromb. Haemost. pmid:9459320
Davì G et al. Increased thromboxane metabolites excretion in liver cirrhosis. 1998 Thromb. Haemost. pmid:9569186
Oosaki R et al. Correlation among urinary eosinophil protein X, leukotriene E4, and 11-dehydrothromboxane B2 in patients with spontaneous asthmatic attack. 1998 Clin. Exp. Allergy pmid:9761018
Lindström T et al. The effect of unreamed and reamed intramedullary nailing on the urinary excretion of prostacyclin and thromboxane A2 metabolites in patients with tibial shaft fractures. 1998 J Trauma pmid:9783614
Obase Y et al. Effects of cysteinyl-leukotriene receptor antagonist, thromboxane A2 receptor antagonist, and thromboxane A2 synthetase inhibitor on antigen-induced bronchoconstriction in patients with asthma. 1998 Chest pmid:9792572
Cullen L et al. Selective cyclooxygenase-2 inhibition by nimesulide in man. 1998 J. Pharmacol. Exp. Ther. pmid:9808683
Praticò D et al. Chronic obstructive pulmonary disease is associated with an increase in urinary levels of isoprostane F2alpha-III, an index of oxidant stress. 1998 Am. J. Respir. Crit. Care Med. pmid:9847257
McAdam BF et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. 1999 Proc. Natl. Acad. Sci. U.S.A. pmid:9874808
Davì G et al. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. 1999 Circulation pmid:9892587